VANCOUVER, British Columbia, September 27, 2022 (GLOBE NEWSWIRE) — BetterLife Pharma Inc. (“BetterLife” or the “Company”) BETTERSUBJECT, an emerging biotech company focused on developing and commercializing innovative treatments for mental disorders, is pleased to file a PCT patent application along with a US application for lysergic acid diethylamide (“LSD”) derivatives, including 2-bromo to announce -LSD. The applications cover compositions of these derivatives for use in treating a variety of neuropsychiatric and neurological disorders including depression, anxiety, cluster headaches and pain.

BetterLife is currently developing a new composition of 2-bromo-LSD (“BETR-001”) which is covered by these patent applications. BETR-001 is a second generation LSD derivative molecule that does not cause hallucinations and is therefore not subject to global controlled substance regulations. Additionally, BETR-001 is synthesized via uncontrolled synthetic pathways and is therefore not subject to regulatory restrictions on controlled substances.

BetterLife is in advanced stages of GMP manufacturing of BETR-001 and is completing the necessary pre-clinical IND-enabling studies for BETR-001. BetterLife expects to submit the BETR-001 IND in the first half of 2023 and begin Phase 1 in healthy subjects.

Ahmad Doroudian, CEO of BetterLife, commented, “The inventions covered by the patent applications are comprehensive and comprise a significant body of data, including the composition of matter, in vitro and in vivo preclinical characterization of BETR-001 , which will be submitted for publication in a prestigious peer-reviewed journal in the near future. Based on the data generated to date, we believe BETR-001 has promise to become an important treatment for a range of mental and neurological disorders, including depression , anxiety, pain and related disorders.”

About BetterLife Pharma

BetterLife Pharma Inc. is an emerging biotechnology company primarily focused on…